NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
07/14/2026
Back to search
Official data from USPTO
R2 REVLIMID/RITUXIMAB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
07/14/2026
Trademark type
Combined
Nice classes
5, 44
Filing date
10/15/2019
Registration date
06/09/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/14/2026
Last transaction
07/14/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
First use anywhere
05/28/2019
First use in commerce
05/28/2019
Drawing code
3
Owner type
03
Owner location
Summit, NJ, US
Examiner
MARTIN, CHRISTINE C
Current location
Historical data usage
Mark description
The mark consists of the letter "R" appearing with the exponent "2" in blue next to the wording "REVLIMID/" with the letters appearing in black and the forward slash appearing in yellow, above the wording "RITUXIMAB" appearing in black.
Holders and representatives
Holders
C. C. (pessoa física)
Representatives
Marilyn F. Kelly Bristol-Myers Squibb Company
Technical classification
Nice Classes
Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of certain cancers; pharmaceutical preparations for the treatment of lymphoma; pharmaceutical preparationscytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; all the aforementioned goods being comprised in part of rituximab
Class 44
Medical information and counseling in the field of pharmaceuticals and safety issues pertaining to pharmaceuticalsproviding medical information in the aforementioned fields by distributing written materials in connection therewith; programs in the nature of providing medical information and counseling in the field of lenalidomide and rituximab and safety issues pertaining to lenalidomide and rituximabproviding medical information in the aforementioned fields by distributing written materials in connection therewith; providing a web site featuring medical information; providing an internet website for medical professionals and medical patients featuring medical information; providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; providing pharmaceutical advice; providing medical informationconsultancy and advisory services; all the aforementioned services relating to rituximab
Publications
History of USPTO decisions and trademark events.
34 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
07/14/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/13/2026
E815
TEAS SECTION 8 & 15 RECEIVED
04/13/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/09/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/09/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/09/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
12/09/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/09/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/09/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/09/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
06/09/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/24/2020
PUBO
PUBLISHED FOR OPPOSITION
03/24/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/04/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/17/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
02/17/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/17/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
02/17/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/17/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
02/13/2020
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
01/28/2020
ALIE
ASSIGNED TO LIE
01/13/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/08/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/07/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/06/2020
GNRT
NON-FINAL ACTION E-MAILED
01/06/2020
CNRT
NON-FINAL ACTION WRITTEN
01/06/2020
DOCK
ASSIGNED TO EXAMINER
12/30/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/22/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/19/2019
NWAP
NEW APPLICATION ENTERED
10/18/2019
Continuous trademark protection
Get notified about every new filing that threatens R2 REVLIMID/RITUXIMAB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.